Health economics and the modern management of psoriasis

British Journal of Dermatology

Volumn 163, Issue 4, 2010, Pages 670-671

  Burden, A D ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

biologic therapy; costs; medical resource use; psoriasis

Indexed keywords

ETANERCEPT;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HUMAN; NOTE; PRIORITY JOURNAL; PSORIASIS; TERTIARY HEALTH CARE; UNITED KINGDOM;

DERMATOLOGIC AGENTS; DRUG COSTS; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; PSORIASIS;

EID: 77957099018     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10006.x     Document Type: Note

References (6)

1. Fonia A, Jackson K, LeReun C et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010 163 : 807 816.
2. Carrascosa JM, Pujol R, Dauden E et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006 20 : 840 845.
3. Schoffski O, Augustin M, Prinz J et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007 5 : 209 218.
4. Colombo G, Altomare G, Peris K et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008 4 : 559 568.
5. Bhosle MJ, Feldman SR, Camacho FT et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006 17 : 294 301.
6. NICE. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103). Available at: http://guidance.nice.org.uk/TA103/Guidance/ Evidence (last accessed 18 August 2010).